Dr. Ziebarth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6025 Lake Rd
Ste 110
Woodbury, MN 55125Phone+1 651-735-7414Fax+1 651-735-1827
Summary
- Gynecologic Oncologist
<https://woodlandsmed.com/physicians/angela-ziebarth-m-d/>.
Education & Training
- University of Alabama Medical CenterFellowship, Gynecologic Oncology, 2010 - 2013
- University of Wisconsin Hospitals and ClinicsResidency, Obstetrics and Gynecology, 2006 - 2010
- University of South Dakota, Sanford School of MedicineClass of 2006
- Gustavus Adolphus CollegeB.A., Biology and Violin Performance, 1998 - 2002
Certifications & Licensure
- FL State Medical License 2013 - 2025
- MN State Medical License 2024 - 2025
- AL State Medical License 2010 - 2013
- WI State Medical License 2008 - 2011
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Award for Best Teaching Faculty APGO/CREOG, 2014
- Vicki Welsh Fund Scholarship for Gynecologic Oncology Training Spelman Medical Foundation, 2011
- Award for Best Teaching Resident University of Wisconsin School of Medicine and Public Health, 2008
- Join now to see all
Publications & Presentations
PubMed
- 34 citationsEDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancerAmber Thompson Bradley, Hui Zheng, Angela Ziebarth, Wayne Sakati, Melissa Branham-O'Connor
Carcinogenesis. 2014-05-01 - 46 citationsEndoglin (CD105) Contributes to Platinum Resistance and Is A Target for Tumor-Specific Therapy in Epithelial Ovarian CancerAngela Ziebarth, Somaira Nowsheen, Adam D. Steg, Monjri Shah, Ashwini A. Katre
Clinical Cancer Research. 2013-01-01 - 11 citationsCompleted versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy.Angela Ziebarth, Haller J. Smith, Mary E. Killian, Nguyet A. Nguyen, Jennifer K. Durst
Gynecologic Oncology. 2012-07-01
Journal Articles
- Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancerZiebarth AJ, Nowsheen S, Steg AD, Shah MM, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner MB, Yang ES, Landen CN Jr, Clin Cancer Res, 1/1/2013
Books/Book Chapters
Abstracts/Posters
- Uterine Carcinosarcoma as a Cancer ClusterWilliams B, Ziebarth A, Burns, J, Annual Meeting of the American Congress of Obstetricians and Gynecologists, 1/7/2017
- Use of Phenazopyridine in Visualizing Ureteral Jet Stream During CystoscopyAntonetti A, Williams B, Ziebarth A, DeCesare S, Annual Meeting of the American Congress of Obstetricians and Gynecologists, 1/7/2016
- Primary ovarian cancer murine xenografts maintain tumor heterogeneity and biologically correlate with patient response to primary chemotherapyZiebarth A, Dobbin Z, Katre A, Steg A, Alvarez R, Conner M, Landen C, Annual Meeting of the Society of Gynecologic Oncologists, 1/24/2012
- Join now to see all
Lectures
- Targeting Endoglin (CD105) induces apoptosis, improves platinum sensitivity both in vivo and in vitro, and is a potential therapeutic target in epithelial ovarian cancer1/23/2011
- High Ascites DcR3 levels are Associated with Poor Tumor Infiltration by CD8+ Lymphocytes in Advanced Ovarian Cancer1/10/2010
- Ascites DcR3 Level is Associated with Poor Prognosis in Advanced Ovarian Cancer1/14/2009
Press Mentions
- Body & Soul: Ovarian Cancer... The Silent KillerSeptember 1st, 2016
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: